Announcing: Haemonetics (NYSE:HAE) Stock Increased An Energizing 253% In The Last Five Years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. Long term Haemonetics Corporation (NYSE:HAE) shareholders would be well aware of this, since the stock is up 253% in five years. On top of that, the share price is up 12% in about a quarter.

Check out our latest analysis for Haemonetics

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During the last half decade, Haemonetics became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

NYSE:HAE Past and Future Earnings, September 13th 2019
NYSE:HAE Past and Future Earnings, September 13th 2019

We know that Haemonetics has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at Haemonetics's financial health with this free report on its balance sheet.

Advertisement

A Different Perspective

It's nice to see that Haemonetics shareholders have received a total shareholder return of 13% over the last year. However, that falls short of the 29% TSR per annum it has made for shareholders, each year, over five years. The pessimistic view would be that be that the stock has its best days behind it, but on the other hand the price might simply be moderating while the business itself continues to execute. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

MI
mitchell_lawler
mitchell_lawler

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it. cover
98
ZO
zoe_vi5fn

Any moat with an opt-out clause for your competitors is just a fence around your own garden.

CO
connor_iwn1g

Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.

Andrew Legget

Great earnings season, but are the earnings real?

Great earnings season, but are the earnings real? cover
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
10

About NYSE:HAE

Haemonetics

A medical technology company, provides a suite of hospital technologies solutions.

Reasonable growth potential and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
ONCY logo
Lou_Basenese on Oncolytics Biotech ·

The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech

Fair Value:US$3.575.5% undervalued
23 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
TR
tripledub
Recommended Voice
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$5861.4% undervalued
59 users have followed this narrative
3 users have commented on this narrative
34 users have liked this narrative
TA
Talos
Emerging Author
VOYG logo
Talos on Voyager Technologies ·

The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era

Fair Value:US$385.291.1% undervalued
61 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
IV
Emerging Author
UBER logo
Ivoed on Uber Technologies ·

Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides

Fair Value:US$11632.1% undervalued
13 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

AC
INTC logo
achillez_97613 on Intel ·

Fair Value = $110, Bull = $150, Bear = $65.

Fair Value:US$56.0559.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
AGFB logo
RecMag on Agfa-Gevaert ·

Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.

Fair Value:€5.3991.4% undervalued
28 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LU
LunaRodas
FRO logo
LunaRodas on Frontline ·

FRO | Frontline: What They Said vs. What They Did

Fair Value:US$34.0729.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
365 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9122.3% overvalued
214 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0943.9% undervalued
239 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative